{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:32:14Z","timestamp":1795174334634,"version":"4.10.3"},"reference-count":53,"publisher":"American Association for Cancer Research (AACR)","issue":"17","funder":[{"name":"U.S. Department of Defense","award":["BC170330"],"award-info":[{"award-number":["BC170330"]}],"id":[{"id":"https:\/\/ror.org\/0447fe631","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Cancer Institute","award":["P30 CA091842"],"award-info":[{"award-number":["P30 CA091842"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>In metastatic breast cancer, HER2-activating mutations frequently co-occur with mutations in PIK3CA, TP53, or CDH1. Of these co-occurring mutations, HER2 and PIK3CA are the most commonly comutated gene pair, with approximately 40% of HER2-mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we generated genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids. HP breast cancers showed accelerated tumor formation in vivo and increased invasion and migration in in vitro assays. HP breast cancer cells were resistant to the pan-HER tyrosine kinase inhibitor, neratinib, but were effectively treated with neratinib plus the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan. Proteomic and RNA-seq analysis of HP breast cancers identified increased gene expression of cyclin D1 and p21WAF1\/Cip1 and changes in cell-cycle markers. Combining neratinib with CDK4\/6 inhibitors was another effective strategy for treating HP breast cancers, with neratinib plus palbociclib showing a statistically significant reduction in development of mouse HP tumors as compared to either drug alone. The efficacy of both the neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations was validated using a human breast cancer patient-derived xenograft with very similar HER2 and PIK3CA mutations to the HP mice. Further, these two drug combinations effectively treated spontaneous lung metastasis in syngeneic mice transplanted with HP breast cancer organoids. This study provides valuable preclinical data to support the ongoing phase 1 clinical trials of these drug combinations in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>In HER2-mutated breast cancer, PIK3CA mutation activates p21\u2013CDK4\/6\u2013cyclin D1 signaling to drive resistance to HER2-targeted therapies, which can be overcome using CDK4\/6 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-3558","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T09:28:06Z","timestamp":1685957286000},"page":"2839-2857","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Breast Cancer Mutations\n                    <i>HER2V777L<\/i>\n                    and\n                    <i>PIK3CAH1047R<\/i>\n                    Activate the p21\u2013CDK4\/6\u2013Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance"],"prefix":"10.1158","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5321-1459","authenticated-orcid":false,"given":"Xiaoqing","family":"Cheng","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6931-8496","authenticated-orcid":false,"given":"Yirui","family":"Sun","sequence":"additional","affiliation":[{"name":"2Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5923-7883","authenticated-orcid":false,"given":"Maureen","family":"Highkin","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1970-5460","authenticated-orcid":false,"given":"Nagalaxmi","family":"Vemalapally","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8608-0755","authenticated-orcid":false,"given":"Xiaohua","family":"Jin","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7054-4033","authenticated-orcid":false,"given":"Brandon","family":"Zhou","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0292-1552","authenticated-orcid":false,"given":"Julie L.","family":"Prior","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-3726","authenticated-orcid":false,"given":"Ashley R.","family":"Tipton","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-7249","authenticated-orcid":false,"given":"Shunqiang","family":"Li","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-1363","authenticated-orcid":false,"given":"Anton","family":"Iliuk","sequence":"additional","affiliation":[{"name":"4Tymora Analytical Operations, West Lafayette, Indiana."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3133-6717","authenticated-orcid":false,"given":"Samuel","family":"Achilefu","sequence":"additional","affiliation":[{"name":"3Department of Radiology, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-9745","authenticated-orcid":false,"given":"Ian S.","family":"Hagemann","sequence":"additional","affiliation":[{"name":"5Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri."},{"name":"6Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-5799","authenticated-orcid":false,"given":"John R.","family":"Edwards","sequence":"additional","affiliation":[{"name":"2Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."},{"name":"6Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-8894","authenticated-orcid":false,"given":"Ron","family":"Bose","sequence":"additional","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri."},{"name":"6Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"2025112418023253100_bib1","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"key":"2025112418023253100_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"2025112418023253100_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1158\/2159-8290.CD-12-0349","article-title":"Activating HER2 mutations in HER2 gene amplification negative breast cancer","volume":"3","author":"Bose","year":"2013","journal-title":"Cancer Discov"},{"key":"2025112418023253100_bib4","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jcmgh.2021.04.012","article-title":"HER2 and APC mutations promote altered crypt-villus morphology and marked hyperplasia in the intestinal epithelium","volume":"12","author":"Murray","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025112418023253100_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/2159-8290.CD-19-0966","article-title":"Efficacy and determinants of response to HER kinase inhibition in HER2-mutant metastatic breast cancer","volume":"10","author":"Smyth","year":"2020","journal-title":"Cancer Discov"},{"key":"2025112418023253100_bib6","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-21-3418","article-title":"The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer","volume":"28","author":"Ma","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112418023253100_bib7","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.1158\/1078-0432.CCR-17-0900","article-title":"Neratinib efficacy and circulating tumor DNA detection of HER2 mutations in HER2 nonamplified metastatic breast cancer","volume":"23","author":"Ma","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2025112418023253100_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"2025112418023253100_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S1470-2045(20)30444-7","article-title":"Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial","volume":"21","author":"Turner","year":"2020","journal-title":"Lancet Oncol"},{"key":"2025112418023253100_bib10","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.ccell.2021.06.001","article-title":"Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2\/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity","volume":"39","author":"Hanker","year":"2021","journal-title":"Cancer Cell"},{"key":"2025112418023253100_bib11","doi-asserted-by":"crossref","first-page":"14372","DOI":"10.1073\/pnas.1303204110","article-title":"Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies","volume":"110","author":"Hanker","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112418023253100_bib12","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1200\/JCO.2014.55.2158","article-title":"PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer","volume":"33","author":"Majewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"2025112418023253100_bib13","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/febs.12175","article-title":"Mouse models of PIK3CA mutations: one mutation initiates heterogeneous mammary tumors","volume":"280","author":"Koren","year":"2013","journal-title":"FEBS J"},{"key":"2025112418023253100_bib14","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1158\/0008-5472.CAN-10-0738","article-title":"Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation","volume":"71","author":"Adams","year":"2011","journal-title":"Cancer Res"},{"key":"2025112418023253100_bib15","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/onc.2012.53","article-title":"Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations","volume":"32","author":"Yuan","year":"2013","journal-title":"Oncogene"},{"key":"2025112418023253100_bib16","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.celrep.2018.09.056","article-title":"Cdh1 and Pik3ca mutations cooperate to induce immune-related invasive lobular carcinoma of the breast","volume":"25","author":"An","year":"2018","journal-title":"Cell Rep"},{"key":"2025112418023253100_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","article-title":"A living biobank of breast cancer organoids captures disease heterogeneity","volume":"172","author":"Sachs","year":"2018","journal-title":"Cell"},{"key":"2025112418023253100_bib18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s43018-022-00337-6","article-title":"A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology","volume":"3","author":"Guillen","year":"2022","journal-title":"Nat Cancer"},{"key":"2025112418023253100_bib19","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","article-title":"Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids","volume":"16","author":"Dekkers","year":"2021","journal-title":"Nat Protoc"},{"key":"2025112418023253100_bib20","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","article-title":"High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells","volume":"111","author":"Mathews Griner","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112418023253100_bib21","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/nmeth.4535","article-title":"BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance","volume":"15","author":"Duarte","year":"2018","journal-title":"Nat Methods"},{"key":"2025112418023253100_bib22","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.devcel.2008.03.003","article-title":"Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis","volume":"14","author":"Ewald","year":"2008","journal-title":"Dev Cell"},{"key":"2025112418023253100_bib23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2025112418023253100_bib24","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"2025112418023253100_bib25","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","article-title":"RSeQC: quality control of RNA-seq experiments","volume":"28","author":"Wang","year":"2012","journal-title":"Bioinformatics"},{"key":"2025112418023253100_bib26","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2025112418023253100_bib27","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112418023253100_bib28","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","article-title":"TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data","volume":"44","author":"Colaprico","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2025112418023253100_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3390\/toxins13090654","article-title":"Proteomic identification and quantification of snake venom biomarkers in venom and plasma extracellular vesicles","volume":"13","author":"Willard","year":"2021","journal-title":"Toxins (Basel)"},{"key":"2025112418023253100_bib30","doi-asserted-by":"crossref","first-page":"e1009861","DOI":"10.1371\/journal.ppat.1009861","article-title":"Integrative multi-omics profiling reveals cAMP-independent mechanisms regulating hyphal morphogenesis in Candida albicans","volume":"17","author":"Min","year":"2021","journal-title":"PLoS Pathog"},{"key":"2025112418023253100_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41598-020-58323-w","article-title":"Evaluation of SPP1\/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer","volume":"10","author":"G\u00f6thlin Eremo","year":"2020","journal-title":"Sci Rep"},{"key":"2025112418023253100_bib32","doi-asserted-by":"crossref","first-page":"e201700232","DOI":"10.1002\/jbio.201700232","article-title":"Perfusion-based fluorescence imaging method delineates diverse organs and identifies multifocal tumors using generic near-infrared molecular probes","volume":"11","author":"Miller","year":"2018","journal-title":"J Biophotonics"},{"key":"2025112418023253100_bib33","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"key":"2025112418023253100_bib34","first-page":"53609","article-title":"Bioluminescence-based tumor quantification method for monitoring tumor progression and treatment effects in mouse lymphoma models","volume":"113","author":"Cosette","year":"2016","journal-title":"J Vis Exp"},{"key":"2025112418023253100_bib35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12929-018-0430-8","article-title":"Annexin A2-mediated cancer progression and therapeutic resistance in nasopharyngeal carcinoma","volume":"25","author":"Chen","year":"2018","journal-title":"J Biomed Sci"},{"key":"2025112418023253100_bib36","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/acel.12639","article-title":"Cooperation between p21 and Akt is required for p53-dependent cellular senescence","volume":"16","author":"Kim","year":"2017","journal-title":"Aging Cell"},{"key":"2025112418023253100_bib37","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.ccr.2012.04.027","article-title":"p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer","volume":"21","author":"Jackson","year":"2012","journal-title":"Cancer Cell"},{"key":"2025112418023253100_bib38","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.3748\/wjg.v21.i42.12150","article-title":"Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy","volume":"21","author":"Ohkoshi","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2025112418023253100_bib39","first-page":"5390","article-title":"The phosphatidylinositol 3-kinase\/AKT signal transduction pathway plays a critical role in the expression of p21WAF1\/CIP1\/SDI1 induced by cisplatin and paclitaxel","volume":"60","author":"Mitsuuchi","year":"2000","journal-title":"Cancer Res"},{"key":"2025112418023253100_bib40","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/emboj\/18.6.1571","article-title":"The p21(Cip1) and p27(Kip1) CDK \u2018inhibitors\u2019 are essential activators of cyclin D-dependent kinases in murine fibroblasts","volume":"18","author":"Cheng","year":"1999","journal-title":"EMBO J"},{"key":"2025112418023253100_bib41","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1101\/gad.11.7.847","article-title":"New functional activities for the p21 family of CDK inhibitors","volume":"11","author":"LaBaer","year":"1997","journal-title":"Genes Dev"},{"key":"2025112418023253100_bib42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"2025112418023253100_bib43","doi-asserted-by":"crossref","first-page":"e44571","DOI":"10.7554\/eLife.44571","article-title":"Stress-mediated exit to quiescence restricted by increasing persistence in CDK4\/6 activation","volume":"9","author":"Yang","year":"2020","journal-title":"eLife"},{"key":"2025112418023253100_bib44","doi-asserted-by":"crossref","first-page":"8517","DOI":"10.1074\/jbc.M108867200","article-title":"p21(Cip1) promotes cyclin D1 nuclear accumulation via direct inhibition of nuclear export","volume":"277","author":"Alt","year":"2002","journal-title":"J Biol Chem"},{"key":"2025112418023253100_bib45","doi-asserted-by":"crossref","first-page":"210125","DOI":"10.1098\/rsob.210125","article-title":"Palbociclib-mediated cell cycle arrest can occur in the absence of the CDK inhibitors p21 and p27","volume":"11","author":"Pennycook","year":"2021","journal-title":"Open Biol"},{"key":"2025112418023253100_bib46","doi-asserted-by":"crossref","first-page":"eaaw2106","DOI":"10.1126\/science.aaw2106","article-title":"p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition","volume":"366","author":"Guiley","year":"2019","journal-title":"Science"},{"key":"2025112418023253100_bib47","doi-asserted-by":"crossref","first-page":"628690","DOI":"10.3389\/fphar.2021.628690","article-title":"Activation of PI3K\/AKT\/mTOR pathway causes drug resistance in breast cancer","volume":"12","author":"Dong","year":"2021","journal-title":"Front Pharmacol"},{"key":"2025112418023253100_bib48","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"Berns","year":"2007","journal-title":"Cancer Cell"},{"key":"2025112418023253100_bib49","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Nagata","year":"2004","journal-title":"Cancer Cell"},{"key":"2025112418023253100_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2009.27.7814","article-title":"Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers","volume":"29","author":"Dave","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025112418023253100_bib51","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-15-2499","article-title":"Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer","volume":"22","author":"Baselga","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2025112418023253100_bib52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ctrv.2017.07.005","article-title":"Phosphoinositide 3-kinase (PI3K) pathway inhibitors in solid tumors: from laboratory to patients","volume":"59","author":"Janku","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2025112418023253100_bib53","doi-asserted-by":"crossref","first-page":"e2100370","DOI":"10.1200\/PO.21.00370","article-title":"PIK3CA mutations drive therapeutic resistance in human epidermal growth factor receptor 2-positive breast cancer","volume":"6","author":"Rasti","year":"2022","journal-title":"JCO Precis Oncol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-3558\/3338920\/can-22-3558.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/17\/2839\/3358866\/2839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/83\/17\/2839\/3358866\/2839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T23:02:56Z","timestamp":1764025376000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/83\/17\/2839\/728592\/Breast-Cancer-Mutations-HER2V777L-and-PIK3CAH1047R"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":53,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,6,5]]},"published-print":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-3558","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.30701368","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028066.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028063.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028060","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701371","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028057.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701383","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071621.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028066","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071621","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071624.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028048.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028054","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028048","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071618.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028054.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028051.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071633.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071627.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071636.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701377","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071630.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028060.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701380","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071630","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028051","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028063","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701374","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.30701386","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.27028057","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071624","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.24071618","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6816236.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6816236.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6816236","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]}}}